CClinicalTrials.gg
Sign In
CompletedNCT02280811Updated Sep 6, 2017Results posted

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

A Phase 1/2 interventional study of Fludarabine and Cyclophosphamide in Vaginal Cancer, Cervical Cancer and Anal Cancer, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Background:

The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. Researchers want to test this on human papilloma virus (HPV)-associated cancers.

Objective:

  • The purpose of this study is to determine a safe number of these cells to infuse and to see if these particular tumor-fighting cells (Anti-HPV E6) can shrink tumors associated with HPV and test the toxicity of this treatment.

Eligibility:

  • Adults age 18-66 with an HPV-16-associated cancer.

Design:

  • Work up stage: Patients will be seen as an outpatient at the National Institutes of Health (NIH) clinical Center and undergo a history and physical examination, scans, x-rays, lab tests, and other tests as needed
  • Leukapheresis: If the patients meet all of the requirements for the study they will undergo leukapheresis to obtain white blood cells to make the anti HPV E6 cells. {Leukapheresis is a common procedure, which removes only the white blood cells from the patient.}
  • Treatment: Once their cells have grown, the patients will be admitted to the hospital for the conditioning chemotherapy, the anti HPV E6 cells and aldesleukin. They will stay in the hospital for about 4 weeks for the treatment.

Follow up: Patients will return to the clinic for a physical exam, review of side effects, lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1 year as long as their tumors are shrinking. Follow up visits take up to 2 days.

Read the detailed description

BACKGROUND:

  • Metastatic or refractory/recurrent human papillomavirus (HPV)-16+ cancers (cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers) are incurable and poorly palliated by standard therapies.
  • HPV-16+ cancers constitutively express the HPV-16 E6 oncoprotein, which is absent from healthy human tissues.
  • Administration of T cell receptor (TCR) gene engineered T cells can induce objective tumor responses in certain malignancies.
  • T cells genetically engineered with a TCR targeting HPV-16 E6 (E6 TCR) display specific reactivity against human leukocyte antigen serotype within HLA-A A serotype group (HLA-A2+), HPV-16+ target cells.

OBJECTIVES:

Primary Objective

  • To determine a safe dose of administration of autologous T cells transduced with an anti-HPV-16 E6 TCR and aldesleukin to patients following a nonmyeloablative but lymphodepleting preparative regimen.
  • To determine the objective tumor response rate (Complete or Partial Response) and duration in patients with metastatic or recurrent/refractory HPV-16+ cancers treated with this regimen.

ELIGIBILITY:

  • Patients greater than or equal to 18 years old and less than or equal to 70 years old with metastatic or refractory/recurrent HPV-16+ cancer.
  • Prior first line systemic therapy is required unless the patient declines standard treatment.
  • Patients must be HLA-A 02:01-positive.

DESIGN:

  • Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen of cyclophosphamide and fludarabine
  • On day 0 patients will receive transduced lymphocytes and then begin high dose aldesleukin
  • The study will begin with a phase I dose escalation. After the maximum tolerated dose (MTD) cell dose has been determined, the patients will be enrolled into the phase II portion of the study.
  • Clinical and immunologic response will be evaluated about 4 to 6 weeks after treatment and then about every 1-6 months until disease progression
  • Following a dose escalation phase of 9 to 18 patients, initially 21 evaluable patients will be enrolled in the phase II portion of the study. If 0 to 1 of the 21 patients experiences a clinical response, then no further patients will be enrolled. If 2 or more of the first 21 evaluable patients enrolled have a clinical response, then accrual will continue until a total of 41 evaluable patients have been enrolled. The accrual ceiling will be set at 61 patients. Provided that about 1 patient every 6 weeks will be enrolled onto this trial, approximately 4 years may be needed to accrue the maximum number of patients.
02

Conditions studied

  • Vaginal Cancer
  • Cervical Cancer
  • Anal Cancer
  • Penile Cancer
  • Oropharyngeal Cancer

Keywords

  • HPV positive
  • Metastatic
  • Diet
  • Screening
  • Risk Factors
  • Colorectal adenoma
  • Refractory
  • Immunotherapy
  • Reproductive Cancers
03

In context

Anus Neoplasms

266 studies on the registry are indexed under Anus Neoplasms; 71 are open to participants now.

This study's enrollment of 12 is below the median of 70 across 182 interventional studies indexed under Anus Neoplasms.

Browse Anus Neoplasms studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,506 studies on the registry; 334 are open to participants now.

Of its 402 completed or terminated interventional studies of FDA-regulated products, 365 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Measurable metastatic or refractory/recurrent human papilloma virus (HPV-16+) cancer (determined by in situ hybridization (ISH) or a polymerase chain reaction (PCR)-based test).
  2. Patients must be human leukocyte antigens (HLA-A) 02:01-positive.
  3. All patients must have received prior first line standard therapy or declined standard therapy, and have been either non-responders (progressive disease) or have recurred.
  4. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.
  5. Greater than or equal to 18 years of age and less than or equal to 70 years of age.
  6. Able to understand and sign the Informed Consent Document.
  7. Willing to sign durable power of attorney
  8. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.
  9. Life expectancy of greater than 3 months.
  10. Patients of both genders must be willing to practice birth control from the time of enrollment on this study up to 4 months after treatment. Patients must be willing to undergo testing for HPV-16 prior to becoming pregnant.
  11. Women of child bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.

  12. Serology:

    • Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus are less responsive to the experimental treatment and more susceptible to its toxicities.)
    • Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by reverse transcription polymerase chain reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA) negative.

  13. Hematology:

    • Absolute neutrophil count greater than 1000/mm\^3 without the support of filgrastim.
    • White blood cell (WBC) greater than or equal to 3000/mm\^3
    • Platelet count greater than or equal 100,000/mm\^3
    • Hemoglobin greater than 8.0 g/dL

  14. Chemistry:

    • Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to 2.5 times the upper limit of normal
    • Serum creatinine less than or equal to 1.6 mg/dL
    • Total bilirubin less than or equal to to 1.5 mg/dL, except in patients with Gilberts Syndrome who must have a total bilirubin less than 3.0 mg/dL
  15. More than 4 weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Women of childbearing potential who are pregnant or breastfeeding. There are potentially dangerous side effects of the treatment on the fetus or infant.
  2. Active systemic infections (for e.g.: requiring anti-infective treatment), coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.
  3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).
  4. Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).
  5. Concurrent systemic steroid therapy.
  6. History of severe immediate hypersensitivity reaction to cyclophosphamide or fludarabine.
  7. History of coronary revascularization or ischemic symptoms.
  8. Documented left ventricular ejection fraction (LVEF) of less than or equal to 45% tested. The following patients will undergo cardiac evaluations

a. clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or

b. age greater than or equal 60 years old

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    T Cell Receptor Immunotherapy

    patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin

    Drug: Fludarabine · Drug: Cyclophosphamide · Biological: E6 TCR · Drug: Aldesleukin

Interventions

  • DrugFludarabine

    Patients will receive Fludarabine 25 mg/m\^2/day for 5 days.

    Also known as: Fludara

  • DrugCyclophosphamide

    Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days

    Also known as: Cytoxan

  • BiologicalE6 TCR

    On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)

  • DrugAldesleukin

    Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).

    Also known as: IL-2

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    The MTD is the highest dose at which ≤1 of 6 patients experienced a dose limiting toxicity (DLT) or the highest dose level studied if DLTs are not observed at any of the dose levels.

    Time frame: participants were followed for the duration of hospital stay, an average of 3 weeks

  2. Objective Tumor Response Rate (Complete or Partial Response)

    Objective tumor response rate is defined as the number of participants with a complete or partial response per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

    Time frame: 4 years

  3. Duration of Response

    Duration of response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progression is at least a 20% increase in the sum of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: up to one year

Secondary outcomes

  1. Number of Participants With Serious and Non-serious Adverse Events

    Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

    Time frame: 19 months and 7 days

  2. Number of Participants With a Dose Limiting Toxicity (DLT)

    A dose limiting toxicity is all Grade 3 and greater toxicities with the exception of myelosuppression, defined as lymphopenia, neutropenia, decreased hemoglobin, and thrombocytopenia, due to chemotherapy preparative regimen. Aldesleukin expected toxicities as defined in Appendix 2 and 3 of the protocol. Expected chemotherapy toxicities as defined in the pharmaceutical information section. Immediate hypersensitivity reactions (excluding symptomatic bronchospasm and grade 4 hypotension) occurring within 2 hours of cell infusion (related to cell infusion) that are reversible to a grade 2 or less within 24 hours of cell administration with standard therapy. Grade 3 fever. Events that are clearly related to the patient's disease.

    Time frame: 19 months and 7 days

  3. Percentage of Cluster of Differentiation 3 (CD3+) Cells That Are E6 T-Cell Receptor Memory of Circulating T-Cells in Responders and Non-responders

    Detection of E6 TCR T cells in patients peripheral blood leukocytes (PBL)/apheresis samples by flow cytometry.

    Time frame: One month after treatment

  4. Expression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells

    Presence of PD-1 on circulating lymphocytes by flow cytometry one month after treatment.

    Time frame: one month after treatment

07

Results

Posted Aug 2, 2017

Participant flow

Drug Administration
Participant flow — Drug Administration
MilestoneHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2
Started12162
Completed12162
Not completed00000
Retreated at the MTD
Participant flow — Retreated at the MTD
MilestoneHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2
Started00001
Completed00001
Not completed00000

Outcome measures

PrimaryMaximum Tolerated Dose (MTD)

The MTD is the highest dose at which ≤1 of 6 patients experienced a dose limiting toxicity (DLT) or the highest dose level studied if DLTs are not observed at any of the dose levels.

Time frame:
participants were followed for the duration of hospital stay, an average of 3 weeks
Reported as:
Number · # of cells x 10^11
Maximum Tolerated Dose (MTD)
# of cells x 10^11All Treated Subjects
Maximum Tolerated Dose (MTD)2
PrimaryObjective Tumor Response Rate (Complete or Partial Response)

Objective tumor response rate is defined as the number of participants with a complete or partial response per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

Time frame:
4 years
Reported as:
Number · participants
Objective Tumor Response Rate (Complete or Partial Response)
participantsHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2
Complete Response (CR)00000
Partial Response (PR)00020
PrimaryDuration of Response

Duration of response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progression is at least a 20% increase in the sum of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
up to one year
Reported as:
Mean · months
Duration of Response
monthsHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2
Duration of ResponseNA (NA to NA)NA (NA to NA)NA (NA to NA)1.5 (0 to 6)NA (NA to NA)
SecondaryNumber of Participants With Serious and Non-serious Adverse Events

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Time frame:
19 months and 7 days
Reported as:
Count of participants · Participants
Number of Participants With Serious and Non-serious Adverse Events
ParticipantsHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2
Number of Participants With Serious and Non-serious Adverse Events12162
SecondaryNumber of Participants With a Dose Limiting Toxicity (DLT)

A dose limiting toxicity is all Grade 3 and greater toxicities with the exception of myelosuppression, defined as lymphopenia, neutropenia, decreased hemoglobin, and thrombocytopenia, due to chemotherapy preparative regimen. Aldesleukin expected toxicities as defined in Appendix 2 and 3 of the protocol. Expected chemotherapy toxicities as defined in the pharmaceutical information section. Immediate hypersensitivity reactions (excluding symptomatic bronchospasm and grade 4 hypotension) occurring within 2 hours of cell infusion (related to cell infusion) that are reversible to a grade 2 or less within 24 hours of cell administration with standard therapy. Grade 3 fever. Events that are clearly related to the patient's disease.

Time frame:
19 months and 7 days
Reported as:
Count of participants · Participants
Number of Participants With a Dose Limiting Toxicity (DLT)
ParticipantsHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2
Number of Participants With a Dose Limiting Toxicity (DLT)00000
SecondaryPercentage of Cluster of Differentiation 3 (CD3+) Cells That Are E6 T-Cell Receptor Memory of Circulating T-Cells in Responders and Non-responders

Detection of E6 TCR T cells in patients peripheral blood leukocytes (PBL)/apheresis samples by flow cytometry.

Time frame:
One month after treatment
Reported as:
Mean · percentage of cells
Percentage of Cluster of Differentiation 3 (CD3+) Cells That Are E6 T-Cell Receptor Memory of Circulating T-Cells in Responders and Non-responders
percentage of cellsHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2
RespondersNANANA38 (30.1 to 45.9)NA (NA to NA)
Non-responders30.7 (30.7 to 30.7)4.4 (4.4 to 4.4)12.6 (12.6 to 12.6)29.9 (10.4 to 44.4)37.1 (21.7 to 52.5)
SecondaryExpression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells

Presence of PD-1 on circulating lymphocytes by flow cytometry one month after treatment.

Time frame:
one month after treatment
Reported as:
Mean · % PD-1 circulating lymphocytes
Expression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells
% PD-1 circulating lymphocytesHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2
Expression of Programmed Cell Death 1 (PD-1) by Circulating E6 T-Cell Receptor (TCR) T-Cells1 (1 to 1)2 (2 to 2)3 (3 to 3)1 (0 to 3.6)2.2 (0.5 to 3.9)

Adverse events

Collected over 19 months and 7 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HPV-16 E6 mTCR PBL 1x10^9 + HD IL-20/1 (0%)0/1 (0%)1/1 (100%)
HPV-16 E6 mTCR PBL 1x10^10 + HD IL-20/2 (0%)1/2 (50%)2/2 (100%)
HPV-16 E6 mTCR PBL 1x10^11 + HD IL-20/1 (0%)0/1 (0%)1/1 (100%)
HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-20/6 (0%)2/6 (33.3%)6/6 (100%)
HPV-16 E6 mTCR PBL MTD + HD IL-20/2 (0%)2/2 (100%)2/2 (100%)
HPV-16 E6 mTCR PBL MTD + HD IL-2-Retreatment0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2-Retreatment
Febrile neutropeniaInfections and infestations0/10/20/10/62/20/1
Dyspnea (shortness of breath)Respiratory, thoracic and mediastinal disorders0/11/20/10/60/20/1
Hemorrhage, pulmonary/upper respiratory::Bronchopulmonary NOSRespiratory, thoracic and mediastinal disorders0/11/20/10/60/20/1
HypoxiaRespiratory, thoracic and mediastinal disorders0/11/20/10/60/20/1
Obstruction/stenosis of airway::BronchusRespiratory, thoracic and mediastinal disorders0/11/20/10/60/20/1
Prolonged intubation after pulmonary resection (>24 hrs after surgery)Respiratory, thoracic and mediastinal disorders0/11/20/10/60/20/1
Infection (documented clinically or microbiologically)Infections and infestations0/10/20/12/60/20/1
DiarrheaGastrointestinal disorders0/10/20/11/60/20/1
Most frequent other events
Showing 10 of 19
Most frequent other events
EventHPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2-Retreatment
FatigueGeneral disorders1/11/21/11/60/20/1
HemoglobinMetabolism and nutrition disorders1/12/21/14/62/21/1
Infection (documented clinically and microbiologically)Infections and infestations1/10/20/11/60/20/1
LymphopeniaBlood and lymphatic system disorders1/12/21/16/62/21/1
Neutrophils/granulocytes (ANC/AGC)Blood and lymphatic system disorders1/12/21/16/62/21/1
PlateletsBlood and lymphatic system disorders1/12/21/16/62/21/1
Febrile neutropeniaInfections and infestations0/11/21/11/62/20/1
HypotensionCardiac disorders0/10/21/10/60/20/1
Bilirubin (hyperbilirubinemia)Metabolism and nutrition disorders0/11/20/10/60/20/1
Psychosis (hallucinations/delusions)Nervous system disorders0/11/20/10/60/20/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2Total
<=18 years000000
Between 18 and 65 years1215110
>=65 years000112
Age, Continuous
Age, Continuous(years)HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2Total
Mean50.0 ± 034.5 ± 3.546.0 ± 053.5 ± 12.560.0 ± 14.150.5 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2Total
Female1215110
Male000112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2Total
Hispanic or Latino010001
Not Hispanic or Latino1116211
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2Total
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White1116211
More than one race000000
Unknown or Not Reported010001
Region of Enrollment
Region of Enrollment(participants)HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2Total
United States1216212
Baseline Cancer Types
Baseline Cancer Types(Participants)HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2HPV-16 E6 mTCR PBL MTD + HD IL-2Total
Cervical021306
Anal000224
Oropharyngeal000101
Vaginal100001
08

Study locations

1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
09

References and documents

Publications

  • Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med. 2012 Mar 28;4(127):127ps8. doi: 10.1126/scitranslmed.3003634. PubMed 22461638 ↗
  • Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014 Jan;257(1):56-71. doi: 10.1111/imr.12132. PubMed 24329789 ↗
  • Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3. PubMed 21969503 ↗

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02280811
Lead sponsor
National Cancer Institute (NCI)
Responsible party
Christian S. Hinrichs, M.D. (Principal Investigator, National Institutes of Health Clinical Center (CC)) — Principal investigator
First posted
Nov 2, 2014
Start date
Oct 14, 2014
Primary completion
Jun 28, 2016
Completion
Jun 28, 2016
Results posted
Aug 2, 2017
Last update
Sep 6, 2017

Study contacts

Christian S Hinrichs, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Anus Neoplasms→

Other studies from this sponsor

National Cancer Institute (NCI)

Start the discussion